Program
tislelizumab
Also written as “Tislelizumab”, “BGB-A317” and “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Carcinoma, Hepatocellular · Stomach Neoplasms · Hodgkin Disease, led by 21 companies.
Drug pageTislelizumab: every studyMany companies study it; this page follows only the 74 they lead. All 434 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicinesits history only | 539 open or running | phase 3since Nov 27, 2017 | Mar 26, 2015 | Nov 2026phase 2 · NCT03736889 |
| RemeGenits history only | 22 open or running | phase 3since Apr 17, 2025 | Apr 17, 2025 | May 15, 2028phase 3 · NCT06944496 |
| Antengeneits history only | 10 open or running | phase 2since May 25, 2020 | May 25, 2020 | none ahead |
| Beijing Aosaikang Pharmaceuticalits history only | 11 open or running | phase 2since Nov 21, 2022 | Nov 21, 2022 | none ahead |
| Beijing Biostar Pharmaceuticalsits history only | 11 open or running | phase 2since Sep 18, 2026 | Sep 18, 2026 | Sep 20, 2028phase 2 · NCT07842276 |
| BriaCell Therapeuticsits history only | 11 open or running | phase 2since Jun 11, 2024 | Jun 11, 2024 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 3since Nov 9, 2018 | Nov 9, 2018 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 10 open or running | phase 1since Jun 16, 2022 | Jun 16, 2022 | none ahead |
| HUTCHMEDits history only | 10 open or running | phase 2since Sep 23, 2020 | Sep 23, 2020 | none ahead |
| Immix Biopharmaits history only | 11 open or running | phase 2since Jan 4, 2023 | Jan 4, 2023 | none ahead |
| Immune-Onc Therapeuticsits history only | 10 open or running | phase 1since Aug 12, 2022 | Aug 12, 2022 | none ahead |
| Jazz Pharmaceuticals | 11 open or running | phase 3since Nov 5, 2021 | Nov 5, 2021 | none ahead |
| Jiangsu Healthy Life Innovation Medical Technologyits history only | 11 open or running | phase 2since Mar 19, 2024 | Mar 19, 2024 | none ahead |
| Jiangsu Yahong Meditech Co., Ltd aka Asierisits history only | 10 open or running | phase 2since Mar 21, 2021 | Mar 21, 2021 | none ahead |
| Leap Therapeuticsits history only | 10 open or running | phase 2since Apr 23, 2020 | Apr 23, 2020 | none ahead |
| Nanjing Leads Biolabsits history only | 10 open or running | phase 2since Aug 22, 2022 | Aug 22, 2022 | none ahead |
| Novartisits history only | 10 open or running | phase 3since Mar 17, 2023 | Mar 17, 2023 | none ahead |
| Shanghai Gopherwood Biotechits history only | 10 open or running | phase 2since Aug 15, 2022 | Aug 15, 2022 | none ahead |
| Shanghai Kanda Biotechnologyits history only | 11 open or running | phase 2since May 24, 2023 | May 24, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 2since Feb 9, 2025 | Feb 9, 2025 | none ahead |
| Suzhou Zelgen Biopharmaceuticalsits history only | 11 open or running | phase 2since Jul 25, 2025 | Jul 25, 2025 | Dec 2027phase 2 · NCT07099547 |
Also a collaborator on its studies: Myriad Genetic Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Jazz Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named tislelizumabINNProposed as its International Nonproprietary Name in WHO's List 117
- Nov 5, 2021First study: phase 3 study in Stomach NeoplasmsFirst studyNCT05152147 · 920 enrolled · Argentina, Australia, Belgium and more
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The one study Jazz Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05152147Stomach Neoplasms · Argentina, Australia, Belgium and more | 3 | Active, not recruiting | Jul 15, 2026 | 920 |
How it is read
Names in the registry
- “Tislelizumab”, 57 entries
- “BGB-A317”, 2 entries
- “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”, 1 entry
- “Tislelizumab (BGB-A317)”, 1 entry
- “Subcutaneous Tislelizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 13 studies
- Esophageal Squamous Cell Carcinoma, 7 studies
- Carcinoma, Hepatocellular, 5 studies
- Stomach Neoplasms, 4 studies
- Hodgkin Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.